Overview of Myelodysplastic Syndromes

Seminars in Hematology

Volumn 49, Issue 4, 2012, Pages 287-294

  Beris, Photis ^a,b   Georgiou, George ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Hematology Department   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; MOLECULAR MARKER;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; ANEMIA; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLONAL VARIATION; COMORBIDITY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; ERYTHROCYTE TRANSFUSION; FLOW CYTOMETRY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPING; LABORATORY TEST; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; WHO PROGNOSTIC SCORING SYSTEM; WORLD HEALTH ORGANIZATION;

CYTOGENETIC ANALYSIS; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS;

EID: 84867621437     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.07.002     Document Type: Article

References (25)

1. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
2. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
3. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
4. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
5. Valent P., Horny H.P., Bennett J.M., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
6. Brunning R.D., Orazi A., Germing U., et al. Myelodysplastic syndromes/neoplasms. World Health Organization classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues 2008, vol. 2:88-107. IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
7. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 15:2079-2088. 89.
8. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
9. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
10. Bowen T.D., Fenaux P., Hellstrom-Lindberg E., de Witte T. Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. J Clin Oncol 2008, 26:1180.
11. Garcia-Manero G., Shan J., Faderl S., et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008, 22:538-554.
12. Schanz J., Tuchler H., Sole F., et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012, 30:820-829.
13. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
14. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
15. Kantarjian H., O'Brien S., Ravandi F., et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. Cancer 2009, 115:5202-5209.
16. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112. 45-5.
17. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000, 35:181-200.
18. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
19. Naqvi K., Garcia-Manero G., Sardesai S., et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 2011, 29:2240-2246.
20. Kuendgen A., Strupp C., Aivado M., Hildebrandt Barbara, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006, 12:5358-5365.
21. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
22. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
23. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
24. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
25. Szpurka H., Tiu R., Murugesan G., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006, 108:2173-2181.